Eric Singhi, Thoracic Medical Oncologist at MD Anderson Cancer Center, shared a post by Balazs Halmos, Associate Director for Clinical Science at Montefiore Einstein Cancer Center, adding:
“COMPEL(ing) study at WCLC25. Limitations noted below, but in EGFR+ NSCLC with NON-CNS progression on 1L osi, CONTINUING osi w/ chemo improved outcomes: PFS: 8.4 vs 4.4 mo (HR 0.43) Fewer new brain mets: 10% vs 27% Osi to remain our backbone across lines?”
Quoting Balazs Halmos‘s post:
“Very intriguing results presented by Dr Pasello from the COMPEL trial of chemo +\_ osi upon progression on osimertinib in pts w advanced EGFR+ NSCLC While study stopped early and not definitive- strong signals of benefit noted, mainly due to clear CNS protective effect How do these results impact practice esp w changes in frontline tx? Well, from here on it should certainly be a No-Brainer to always consider the CNS compartment through lines of therapy for our EGFR-mutated patients.”
